MTOR and esophageal squamous cell carcinoma: In ESCC, panobinostat inhibited ESCC cell proliferation by inducing cell cycle arrest, while a preclinical assessment showed that quisinostat’s anti-tumor effect is primarily due to blocking the Akt/mTOR and MAPK/ERK signaling pathways that are considered to activate YAP [129,130].